San Diego, CA -- (SBWire) -- 03/20/2018 --Solid Biosciences Inc. is under investigation over possible securities laws violations.
Investors who purchased shares of Solid Biosciences Inc. (NASDAQ: SLDB), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Solid Biosciences Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Cambridge, MA based Solid Biosciences Inc., a life science company, engages in identifying and developing various therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, an adeno-associated viral vector-mediated gene therapy.
On March 14, 2018, Solid Biosciences Inc. announced that its SGT-001 clinical trial had been put on hold by the Food and Drug Administration ("FDA") due to an adverse reaction to the treatment by one of the trial patients.
Shares of Solid Biosciences Inc. (NASDAQ: SLDB) declined from $28.81 per share on March 13, 2018 to $8.95 per share on March 15, 2018.
On March 19, 2018, NASDAQ: SLDB shares closed at $9.17 per share.
Those who purchased shares of Solid Biosciences Inc. (NASDAQ: SLDB) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com
NASDAQ: SLDB Shareholder Notice: Investigation over Possible Securities Laws Violations by Solid Biosciences Inc
An investigation for investors in Solid Biosciences Inc. (NASDAQ: SLDB) shares over potential securities laws violations by Solid Biosciences Inc. was announced and Solid Biosciences Inc. (NASDAQ: SLDB stockholders should contact the Shareholders Foundation.